HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

Öz

Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish Oncology Group (TOG) Project, retrospectively collected data from 423 patients with HR-positive/HER2-negative MBC treated with ribociclib and palbociclib plus letrozole therapy was assessed. Included patients had metastatic first-line therapy and endocrine-sensitive disease. Survival outcomes were compared between HER2-negative and HER2-low patient groups. Conclusion: HER2-low status had no statistically significant impact on survival in patients treated with palbociclib or ribociclib plus letrozole.

Anahtar Kelimeler

• Cyclin-dependent kinase 4/6 inhibitors
• metastatic breast cancer
• HER-low

Hormon reseptörü pozitif, HER2 negatif metastatik meme kanseri tanısıyla ribosiklib veya palbosiklib ile letrozol kombinasyon tedavisi verilen hastalarda HER2-düşük ekspresyonunun önemi

Öz

Amaç: Metastatik meme kanserinin (MMK) en yaygın alt grubunu temsil eden hormon reseptörü (HR) pozitif, insan epidermal büyüme faktörü 2 (HER2) negatif meme kanseridir. Yakın dönemde HER2 negatif tümörler için daha ileri bir alt sınıflandırma olarak HER2-düşük terimi ortaya çıkmıştır. HER2-düşük ekspresyonunun, CDK 4/6 inhibitörleri ve hormonal tedavi kombinasyonuyla tedavi edilen HR-pozitif/HER2-negatif MMK'li hastaların sonuçları üzerindeki etkisine ilişkin sınırlı bilgi bulunmaktadır. Bu nedenle çalışmamızda bu hasta grubu için HER2-düşük durumuna göre sağkalım parametrelerini değerlendirdik. Gereç ve Yöntemler: Türk Onkoloji Grubu (TOG) Projesi olarak Türkiye genelindeki 43 farklı tıbbi onkoloji merkezinden retrospektif olarak veri toplandı. Haziran 2016 ile Ağustos 2022 arasındaki dönemde Ribosiklib veya Palbosiklib ile letrozol kombinasyon tedavisi verilmiş HR-pozitif/HER2-negatif MMK'li 423 hastadan retrospektif olarak toplanan veriler değerlendirildi. Dahil edilen hastalar metastatik birinci basamak olarak tedaviye başlanan ve endokrin duyarlı hastalığa sahipti. Hastaların sağkalım sonuçları, HER2-negatif ve HER2- düşük hasta grubu arasında kıyaslandı. Sonuç: HER2-düşük durumu, palbosiklib veya ribosiklib ile letrozol tedavisi alan hastalarda sağkalım üzerinde istatistiksel olarak anlamlı bir etki göstermedi.

Anahtar Kelimeler

• CDK4/6 inhibitörleri
• metastatik meme kanseri
• HER2-düşük ekspresyonu

Kaynakça

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72: 7-33.
2. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016; 17: 425-39.
3. Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016; 375: 1925-36.
4. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 375: 1738-48.
5. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018; 19: 904-15.
6. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol 2018; 36: 2465-72.
7. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 2017; 35: 3638-46.
8. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2020; 6: 116-24.

9. Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol 2020; 38: 1951-62.
10. Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 2021; 7: 1.
11. Horisawa N, Adachi Y, Takatsuka D, Nozawa K, Endo Y, Ozaki Y et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Breast Cancer 2022; 29: 234-41.
12. Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. J Clin Oncol 2020; 38: 1887-96.
13. Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387: 9-20.
14. Frenel JS, Lusque A, Mailliez A, Bachelot T, Uwer L, Mouret Reyn‏ier MA et al. 291P HER2-low metastatic breast cancer (MBC): Management and prognosis of a new breast cancer entity in a real-world setting. Ann Oncol 2021; 32: S491.
15. Hein A, Hartkopf AD, Emons J, Lux MP, Volz B, Taran F-A et al. Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer 2021; 155: 1-12.
16. Gampenrieder SP, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res 2021; 23: 112.
17. Denkert C, Seither F, Schneeweiss A, Link T, Blohmer JU, Just M et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol 2021; 22: 1151-61.
18. Ergun Y, Ucar G, Akagunduz B. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis. Cancer Treat Rev 2023; 115: 102538.
19. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med 2022; 386: 942-50.
20. Finn RS, Rugo HS, Dieras VC, Harbeck N, Im S-A, Gelmon KA et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. J Clin Oncol 2022; 40: LBA1003-LBA.
21. Goetz MP, Toi M, Huober J, Sohn J, Tredan O. MONARCH 3: Interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2– advanced breast cancer. ESMO Congress 2022 Abstract LBA15.
22. Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel BC et al. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncol 2023; 19: 727-36.
23. Bao KKH, Sutanto L, Tse SSW, Man Cheung K, Chan JCH. The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer. JAMA Netw Open 2021; 4: e2133132.
24. Douganiotis G, Kesisis G, Lalla E, Korantzis I, Boukovinas I, Papazisis K. Prognostic Significance of Low HER2 Expression in Patients With Metastatic Hormone Receptor-positive Breast Cancer Treated With First Line CDK4/6 Inhibitors: A Greek Multicenter Real-world Data Analysis. Cancer Diagn Progn 2022; 2: 585-91.
25. Shao Y, Luo Z, Yu Y, Chen Q, He Y, Liu C et al. HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study. Front Endocrinol 2022; 13: 1000704.
26. Lapuchesky LS, Bortz M, Waisberg F, Enrico D. CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression. ASCO Annual Meeting; June 3-7, 2022, Chicago, IL. doi:10.1200/JCO.2022.40.16_suppl.1056.
27. Mouabbi JA, Raghavendra AS, Bassett RL Jr, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer 2022; 8: 131.
28. Önder T, Ateş Ö, Öner I, Karaçin C. Relationship between HER2-low status and efficacy of CDK4/6 inhibitors in advanced breast cancer: a real-world study. Int J Clin Oncol 2024; 29: 972-84.
29. Guliyev M, Şen GA, Gültürk İ, Majidova N, Akdağ G, Ahadzade A et al. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study. Breast Cancer Res Treat 2024; 205: 633-40.
30. Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast 2023; 67: 116-23.